FIELD: pharmaceutics; veterinary medicine.
SUBSTANCE: present invention relates to a pharmaceutical or veterinary composition for the use in preventing and/or treating an infection caused by Middle East respiratory syndrome-related coronavirus (MERS-CoV). The composition differs in that it contains at least one compound selected from apigenin and berberine, or their combination, or combination of berberine and monensin in a suitable pharmaceutical carrier.
EFFECT: obtaining antiviral compositions for the treatment of coronavirus-related infections.
5 cl, 3 dwg
| Title | Year | Author | Number |
|---|---|---|---|
| METHOD FOR PREVENTION OR TREATMENT OF CORONAVIRUS AND OTHER ACUTE RESPIRATORY VIRAL INFECTIONS | 2022 |
|
RU2794315C1 |
| MONOCLONAL ANTIBODIES AGAINST CLAUDIN 1 FOR PREVENTION AND TREATMENT OF HEPATOCELLULAR CARCINOMA | 2016 |
|
RU2770021C2 |
| METHOD FOR PROTECTION AGAINST CORONAVIRUS INFECTION | 2020 |
|
RU2747467C1 |
| ANTIVIRAL COMPOSITION | 2020 |
|
RU2740657C1 |
| ANTIVIRAL COMPOSITION | 2020 |
|
RU2740660C1 |
| MEFLOQUINE AND COMBINATIONS THEREOF FOR TREATING AND PREVENTING A CORONAVIRUS INFECTION | 2020 |
|
RU2763024C1 |
| METHODS OF TREATING CORONAVIRUS INFECTIONS | 2021 |
|
RU2825648C1 |
| COMPOSITIONS OF ANTI-CD6 ANTIBODIES AND METHODS OF TREATING AND REDUCING NEGATIVE CONSEQUENCES OF CORONAVIRUS, INCLUDING COVID-19 | 2021 |
|
RU2828013C1 |
| BIOMARKERS AND APPLICATIONS IN TREATING VIRAL INFECTIONS, INFLAMMATIONS OR CANCER | 2019 |
|
RU2820481C2 |
| USE OF DISULFIRAM IN CORONAVIRUS RESISTANCE | 2021 |
|
RU2829731C1 |
